Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in…
Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical passes the values gate
Price34.49 USD
Fair value53.00
Ethical score70.0/100
Our investment reviews on this name
2026-09-02Read Markdown35.97-4.1% to today ✓
2026-08-02Read Markup40.01-13.8% to today
2026-07-02Read Accumulation38.48-10.4% to today
Our analytic regime reads on this name, dated and marked against today's price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Indivior Pharmaceuticals, Inc. holds its Markdown at $34.49. The statistical read favours the sellers, held for 19 days.
As held on the ledger · 2026-09-11
Phase
Markdown · caution
Quantitative state
The statistical read favours the sellers, held for 19 days
Price at the screen
$34.49
Valuation
12.36 trailing · 7.06 forward price to earnings
Values screen
PASS· score 70.0
Beta
1.11
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
29.23%
Below 33%
Interest-bearing debt is just 29.2% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
37.30%
Below 49%
Money owed to the company is 37.3% of assets, under the 49% limit.
Pass
Revenue purity
1.78%
Below 5%
Only 1.8% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
Fair value range in USD, drawn from the 2026-09-11 screen. The gold marker is the market price at the same screen. A 53.7% margin of safety to the base estimate.
Third-party analyst targets: 4 covering, consensus None. The average target sits +45% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-11 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Addiction treatment at a bargain price
Opioid dependence keeps rising, yet Indivior sells the main buprenorphine medicines that help patients step away from heroin and painkillers. The business is expanding revenue 19 percent a year, turning 20 percent of sales into profit, and trades on a forward multiple of just 9.8 times earnings. Our fair-value estimate sits at 59 dollars against the current 40.54, giving a 46 percent margin of safety while the ethical screen flags the work as clearly useful.
Six analysts see a median target of 50 dollars, so the shares already look cheap on simple numbers. Unknown competitive defences and heavy reliance on one drug family keep the opportunity rating at none, which stops any stronger call. Currency moves, regulatory shifts on addiction medicines, and possible new entrants remain real threats to those margins.
The low multiple may simply reflect those gaps rather than a mispriced winner. Analysis, not advice.
The risks · The things to watch: as a drug manufacturers - specialty & generic name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
INDV trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-09-02Markdown · changed$35.97-10.1%Entry 5
The framework has shifted from markup to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 10.1% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 18% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 178%. Our forward projection puts the odds of a 10% gain over the next month near 35%. The street (6 analysts) rates it strong buy, with a mean price target of $52.
2026-08-02Markup · changed$40.01+4.0%Entry 4
The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 4.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 18% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 178%. Our forward projection puts the odds of a 10% gain over the next month near 35%. The street (6 analysts) rates it strong buy, with a mean price target of $52.
2026-07-18Accumulation$38.48+0.0%Entry 3
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 18% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 178%. Our forward projection puts the odds of a 10% gain over the next month near 35%. The street (6 analysts) rates it strong buy, with a mean price target of $52.
2026-07-03Accumulation$38.48+0.0%Entry 2
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.
2026-07-02Accumulation$38.48Entry 1
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
